Pantai Hospital Kuala Lumpur Advances Adult Congenital Heart Care with First Minimally Invasive PDA Device Closure
The patient, who was initially referred for open-heart surgery involving PDA ligation and ventricular septal defect (VSD) closure, was carefully evaluated by PHKL's multidisciplinary cardiac team. A detailed transoesophageal echocardiogram (TOE) revealed a single tiny VSD that did not require immediate surgical repair, allowing the team to opt for a less invasive, catheter-based approach.
"This case is a testament to multidisciplinary, patient-centred approach," said Dr Siti Laura, Consultant Paediatric Cardiothoracic Surgeon at PHKL. "By opting for a minimally invasive PDA device occlusion, we were able to offer the patient a faster recovery, smaller incision, and significantly reduced scarring."
This successful procedure highlights PHKL's expanding capabilities in adult congenital heart care, a specialised and growing field that requires collaborative planning and tailored interventions. It also reflects the hospital's commitment to delivering innovative, minimally invasive solutions for structural heart conditions in adults — a group often underrepresented in congenital cardiac care
Our ability to perform such procedures reflects the hospital's continuous investment in advanced cardiac technology and our commitment to improving outcomes for patients with congenital heart disease," Dr Siti Laura added. "We will continue to monitor the patient's condition closely — particularly her VSD — to ensure optimal long-term care.
PHKL reinforces its position as a tertiary referral centre and a growing centre of excellence for adult congenital heart disease management in Malaysia. For more information about Paediatric and Congenital Cardiothoracic Services at PHKL, please visit: https://www.pantai.com.my/kuala-lumpur/congenital-cardiothoracic.
-END-
***
Dr Siti Laura Mazalan, Consultant Paediatric and Congenital Cardiothoracic Surgeon
MBBS (University of Malaya, Malaysia), MMed Surg (University Kebangsaan Malaysia, Malaysia), Fellowship in Paediatric Cardiac Surgery (Birmingham Children Hospital, United Kingdom)
Dr. Siti Laura is a highly accomplished Paediatric Cardiothoracic Surgeon deeply committed to serving vulnerable in Malaysia. Her medical journey commenced with an MBBS from the University of Malaya in 1998, followed by a Master of Medicine (Surgery) from Universiti Kebangsaan Malaysia in 2004. Beginning her career at Institute Jantung Negara in 2004, she devoted 14 years to the institution as a Consultant Cardiothoracic Surgeon. Motivated by her dedication to enhancing healthcare, she pursued a transformative one-year Fellowship in Paediatric Cardiac Surgery at Birmingham Children's Hospital in 2010.
In 2020, Dr. Siti Laura joined Serdang Hospital, where she played a pivotal role in establishing the Paediatric Cardiothoracic service, catering to underprivileged children with congenital heart diseases in the nation. She subsequently became a Consultant Paediatric Cardiothoracic Surgeon at Pantai Hospital Kuala Lumpur. Dr Siti Laura's area of interest includes Neonatal and Paediatric Cardiothoracic Surgery, Adult Congenital Cardiac Surgery, Single Ventricle Heart Surgery, ECMO support (Extracorporeal membrane oxygenation), Slide Tracheoplasty Surgery in neonates and paediatric patients and Cardiac Homograft Banking. Dr Siti Laura's expertise and unwavering dedication continue to make a profound impact on the lives of her patients and the healthcare community.
***
About Pantai Hospital Kuala Lumpur
For five decades, Pantai Hospital Kuala Lumpur has been the heartbeat of Kuala Lumpur, steadfastly delivering exceptional care to patients from all walks of life. Since its inception in 1974 with just 68 beds and 20 medical specialists, the hospital has grown into a healthcare icon today with 507 beds, over 200 consultants and counting. Our pursuit of quality healthcare, clinical excellence, and cutting-edge technology is underscored by our service quality and dedication towards clinical research.
This has earned us accreditations from the Malaysian Society for Quality in Health (MSQH) and the Joint Commission International (JCI). Additionally, we hold certification as a Baby-Friendly Hospital and is a preferred hospital in Malaysia by the World Health Organization (WHO). As we celebrate our 50th anniversary, Pantai Hospital Kuala Lumpur looks to the future, unwaveringly committed to continuing its legacy of excellence with world-class healthcare services and innovative treatments for generations to come. Learn more at www.pantai.com.my/kuala-lumpur.
For more information, please contact:Callie Phin, Pantai Hospital Kuala LumpurEmail: callie.phin@pantai.com.my Tel No.: 014-686 7066
For media enquiry:Natasha Loo, PR Lab ConsultancyEmail: tasha@pr-lab.co Tel No.: 010-231 0110
Lim Joe Ee, PR Lab ConsultancyEmail: joe.lim@pr-lab.co Tel No.: 012-635 9839
Ally Chai, PR Lab ConsultancyEmail: ally@pr-lab.co Tel No.: 016-232 7625
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/pantai-hospital-kuala-lumpur-advances-adult-congenital-heart-care-with-first-minimally-invasive-pda-device-closure-302474408.html
SOURCE Pantai Hospital Kuala Lumpur
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
NOVEL IMMUNOLOGIC SURVEILLANCE STUDY PROVIDES NEW INSIGHTS INTO POST-PANDEMIC RETURN OF RESPIRATORY VIRUSES
Ongoing clinical research study in US children documents the rebound of endemic respiratory viruses, builds foundation for expediting future vaccines and treatments AURORA, Colo., Aug. 7, 2025 /PRNewswire/ -- The first paper from a multi-year clinical research study has been published in The Lancet Infectious Diseases: Dynamics of Endemic Virus Re-emergence in Children in the USA Following the COVID-19 Pandemic (2022-2023): A Longitudinal Immunoepidemiologic Surveillance Study and demonstrates how the approach can improve modeling to better predict future outbreaks. The paper shares findings from a multicenter clinical research study, one of many studies that are part of the recently launched PREMISE (Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology) program, led by Dr. Daniel Douek at the National Institutes of Health's (NIH) Vaccine Research Center (VRC). Data collected during the first year of the PREMISE study, 2022-2023, shows for the first time how non-pharmaceutical interventions such as masking and distancing targeted towards SARS-CoV-2 during the pandemic also decreased circulation rates of and population immunity to common respiratory pathogens in children. The study provides new evidence-based insight into what was driving the large post-pandemic rebound in these diseases and enables more accurate predictions for the future. This study is a partnership between PREMISE and clinical research sites at academic institutions led by principal investigator Kevin Messacar, MD, PhD, infectious disease specialist at Children's Hospital Colorado, at the central site at University of Colorado Anschutz Medical Campus and Children's Hospital Colorado with additional study sites at University of North Carolina, Weill Cornell Medicine and the University of Alabama at Birmingham. The PREMISE study conducted immunologic surveillance on children younger than 10 years old, by enrolling them and following them for over a year. Through repeat blood sampling, the team could determine what children at varying young ages had immunity to and what they were susceptible to. Through respiratory sampling during illness, researchers were able to determine what infections they experienced. The data showed that most younger children lacked immunity to many normal respiratory viruses during the pandemic, suggesting they had not been exposed, as they typically would have, due to prevention measures in place. Following the lifting of pandemic measures, the level of immunity rose across all pathogens studied, reflective of the unprecedented widespread resurgence of these viruses in children after the end of the pandemic. While most research studies target a specific disease, samples from PREMISE were tested for many common and emerging respiratory viruses, including RSV, influenza and enterovirus D68 (EV-D68), which can cause the polio-like illness, acute flaccid myelitis. The data allowed experts to recreate past circulation patterns and model predictions for future outbreaks with greater accuracy and precision. They showed that PREMISE data from 2022-23 could be used to accurately predict the subsequent wave of disease of the emerging pathogen EV-D68 that occurred in 2024. "Four cohorts of almost 1,000 children have provided an invaluable bank of samples and data," said lead author Hai Nguyen-Tran, MD, infectious disease specialist at Children's Hospital Colorado and assistant professor at University of Colorado School of Medicine. "These are being used to develop 'on the shelf' medical countermeasures, such as antibody treatments and vaccines, for pathogens of interest. Instead of starting from scratch, this study gives us a head start to understand, predict and prepare for future pandemics." Samples and data from the PREMISE study will also be used to learn which parts of viruses the human immune system attacks to become immune, so teams can better design new antibody treatments and effective vaccines to mimic this response. "In the future, this type of immune surveillance can be used to better understand the impact of public interventions on population immunity and future waves of disease," said Dr. Messacar, who is also a professor at University of Colorado School of Medicine. "PREMISE is a great example of a successful research partnership between NIH scientists and clinical researchers in academia, leading to concrete deliverables such as vaccine candidates and monoclonal antibodies that can directly impact public health." This study is fully funded by a subcontract with Frederick National Laboratory for Cancer Research (FNLCR), currently operated by Leidos Biomedical Research, Inc. through Agreement 21X192QT1. FNLCR funding was provided by the NIH Vaccine Research Center within NIAID. The total project funding is $7.98 million over five years. No financing for this project was supplied by nongovernmental sources. ABOUT CHILDREN'S HOSPITAL COLORADOChildren's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Media Contact: Rachael Fowler, Children's Hospital Colorado 24/7 media line: 303-890-8314media@ View original content to download multimedia: SOURCE Children's Hospital Colorado
Yahoo
2 days ago
- Yahoo
Gentuity LLC Announces Agreement to Collaborate with GE HealthCare to Expand Access to Advanced Intravascular Imaging Platform
SUDBURY, Mass., Aug. 7, 2025 /PRNewswire/ -- Gentuity LLC, a Massachusetts-based medical technology company specializing in next-generation intravascular imaging devices, today announced an agreement with GE HealthCare to collaborate on commercial activities. The collaboration is intended to enhance the availability, adoption, and functionality of highly complementary imaging solutions for interventional cardiology. As part of the agreement, Gentuity and GE HealthCare aim to jointly pursue co-marketing initiatives and technical integration of their respective technologies. GE HealthCare also plans to explore opportunities to expand access to Gentuity's innovative products through its own distribution network in the United States. These products include: High-Frequency OCT Imaging System: A mobile console powered by machine learning technology, offering rapid setup and detailed imaging capabilities. Vis-Rx® Prime Micro-Imaging Catheter: The world's smallest imaging catheter at 1.8F, designed for comprehensive vessel imaging before and after percutaneous coronary intervention (PCI) procedures. "We are thrilled at the opportunity to expand our relationship with GE HealthCare and look forward to bringing our advanced imaging solutions to a broader range of healthcare providers," said Desmond Adler, President of Gentuity. "Our industry best serves our physicians and patients when we thoughtfully combine complementary technologies in a way that amplifies their individual impact, and we see this collaboration as an important enabling step in that direction." Founded in 2015, Gentuity is an established leader in the development of advanced intravascular imaging technologies possessing excellent usability and performance. The company's proprietary platform integrates artificial intelligence tools and user-centric design to reduce operator burden with the goal of improving procedural success, extending the known clinical benefits and cost efficiencies of intravascular imaging to a broader range of patients. "At GE HealthCare, we strive to tell the story of the heart through technologies that help diagnose, treat and monitor cardiovascular conditions," said Jyoti Gera, CEO, CardioVascular and Interventional Solutions at GE HealthCare. "This joint initiative with Gentuity supports this mission and reflects our shared commitment to delivering high-quality medical devices that that enhance patient outcomes and quality of life." For more information about Gentuity's products and this agreement, please visit or contact info@ Forward-Looking Statements This release contains forward looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "aim," "estimate," "potential," "position," and similar expressions. These forward-looking statements may include, but are not limited to, statements about the collaboration, the anticipated outcomes of the collaboration, and any new products or solutions resulting from the collaboration or otherwise. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company's inability to achieve the anticipated benefits of this collaboration, business or commercial disruptions, and unexpected risks and liabilities impacting the Company. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. Media Contact: Gentuity LLCEmail: info@ +1 888-967-7628 About Gentuity LLC: Gentuity LLC is a medical technology company dedicated to developing next-generation intravascular imaging devices. Based in Sudbury, Massachusetts, Gentuity focuses on crossing new frontiers in cardiovascular care so patients can focus on living. View original content to download multimedia: SOURCE Gentuity, LLC
Yahoo
3 days ago
- Yahoo
New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation
Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing late complications HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Following the unveiling of 12-month follow-up results from the pivotal Bridge to HOPE trial during the World Transplant Congress (WTC) 2025 Plenary Session, additional analyses of the data demonstrate that Hypothermic Oxygenated Perfusion (HOPE), in conjunction with the VitaSmartTM Perfusion System, can provide significant cost-savings for hospital systems without compromising quality of care, and reduce the severity of organ rejection, including steroid resistant rejection. The results of these analyses were presented in oral abstract sessions by David Axelrod, MD, University Hospitals Cleveland Medical Center, OH ("Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation") and David J. Reich, MD, FACS, Drexel University, Philadelphia, PA ("Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation"). The data were part of the 12-month follow-up study of the Bridge to Life Ltd. Bridge to Hope clinical trial (HOPE with VitaSmartTM Machine Perfusion System). "Building on the 12‑month follow‑up Bridge to HOPE clinical trial data presented in the Plenary Session, these additional analyses further strengthen the evidence for the value that HOPE used with the VitaSmart™ Perfusion System brings to the transplant community," said Don Webber, CEO and President of Bridge to Life Ltd., sponsor of the Bridge to HOPE clinical trial. "Bridge to Life is committed to partnering with Transplant Centers, Organ Procurement Organizations, and Hospitals to lower total cost of care while delivering the highest‑quality patient outcomes—by shortening hospital stays and reducing post‑transplant complications, including the risk of severe and steroid‑resistant rejection. Our broad presence at WTC 2025 underscores our leadership in advancing transplant science." In the economic analysis, compared with standard static cold storage (SCS), liver transplantation using HOPE reduced initial post-liver transplantation hospital length of stay (10.8 vs. 12.9 days), costs associated with biliary complications (20.2% vs. 24.6%), re-transplants (1.8% vs. 4.5%), and death (2.8% vs. 3.6%). Further, HOPE reduced one-year post-transplant costs by an average of $28,565, according to Centers for Medicare & Medicaid Services (CMS) data. Researchers concluded that HOPE for a minimum 1.5 hours at the recipient hospital reduced the cost of liver transplantation by shortening the index hospitalization and decreasing late complications. Additional financial benefits may include increased organ utilization, reduced staff overtime, and fewer high Model for End-Stage Liver Disease (MELD) transplants. In the review of the organ rejection data, moderate/severe biopsy-proven organ rejection was less common in HOPE than SCS (32% v 67%, p=.033). Ten patients developed steroid resistant organ rejection: one in the HOPE cohort and nine in the SCS group (4% v 43%, p=.003). Researchers concluded that while the prevalence of organ rejection was similar in HOPE and SCS, HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection. These results highlight the immunomodulatory benefits of HOPE and warrant further research. About Bridge to Life™ LtdBridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally. 1VitaSmart™ is CE Marked and available for sale in several markets outside of the United States. VitaSmart™ is pending FDA approval in the United States. View original content to download multimedia: SOURCE Bridge to Life, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
